ReproCELL
ReproCELL Incorporated
Company highlights
The largest segment by revenue is 研究支援事業, at 87.4% of the total.
Key figures
Period Apr 2025 to Mar 2026ConsolidatedJapanese GAAP
Company profile
Tables scroll sideways
Disclosed data
Business activities and revenue composition
ReproCELL
Revenue and profit by business segment
Period Apr 2025 to Mar 2026Source Annual securities reportsConsolidated・Disclosed
| Business | Net sales to external customers | Ordinary income | ||||
|---|---|---|---|---|---|---|
| This year | Share | Last year | This year | Margin | Last year | |
| 研究支援事業 | ¥2.0 billion | 87.4% | ¥2.4 billion | ¥96.52 million | 4.9% | ¥0.6 billion |
| Medical business | ¥0.3 billion | 12.6% | ¥0.6 billion | ¥-43.91 million | -15.6% | ¥0.2 billion |
| Total of the businesses | ¥2.2 billion | 100.0% | ||||
Revenue and profit
ReproCELL
Period Apr 2025 to Mar 2026Source Annual securities reports
Amounts by account
| Group | Account | Amount | Consolidated / Non-consolidated |
|---|---|---|---|
| Selling, general and administrative expenses | Research and development expenses | ¥0.6 billion | Consolidated |
| Salaries and allowances | ¥0.5 billion | Consolidated | |
| Fee expenses | ¥0.1 billion | Consolidated | |
| Directors' compensations | ¥62.40 million | Consolidated | |
| Taxes and dues | ¥49.75 million | Parent only | |
| Share-based payment expenses | ¥46.33 million | Parent only | |
| Depreciation | ¥19.27 million | Consolidated | |
| Bonuses and allowance | ¥5.54 million | Consolidated | |
| Provision of allowance for doubtful accounts | ¥5.50 million | Consolidated | |
| Transportation and communication expenses | ¥3.78 million | Parent only | |
| Provision for bonuses | ¥3.55 million | Consolidated | |
| Amortization of goodwill | ¥2.71 million | Consolidated | |
| Profit by stage | Gross profit (loss) | ¥1.0 billion | Consolidated |
| Operating income | ¥-0.9 billion | Consolidated | |
| Net income | ¥-0.6 billion | Consolidated | |
| Ordinary income | ¥-0.6 billion | Consolidated |
ReproCELL
Selling, general and administrative expenses
Period Apr 2025 to Mar 2026Source Annual securities reports
- Research and development expenses ¥0.6 billion
- Salaries and allowances ¥0.5 billion
- Fee expenses ¥0.1 billion
- Directors' compensations ¥0.1 billion
- Taxes and dues ¥0.0 billion
- Share-based payment expenses ¥0.0 billion
- Other (not itemized) ¥0.5 billion
Performance, financial position and capital allocation
Long-term changes in performance
ReproCELL
Long-term revenue, profit and asset trends
Period 2013 to 2026Source Annual securities reportsDisclosed
ReproCELL
Recent performance trends
Source Annual securities reports
Year-on-year comparison
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales | ¥2.2B | ¥3.0B | ¥2.4B | ¥3.0B | ¥2.2B |
| Year on year (%) | +73.7%◆ | +32.2%◆ | -17.8% | +22.7%◆ | -25.0%◆ |
| Ordinary income (loss) | -¥0.5B | -¥0.1B | ¥0.0B | ¥0.0B | -¥0.6B |
| Change from prior year | 0.64x | 0.24x | loss to profit◆ | +12.1% | profit to loss◆ |
| Ordinary income (loss) as a share of Net sales | -22.7% | -4.1% | 1.7% | 1.5% | -26.0% |
| Change (percentage points) | +38.6 points◆ | +18.7 points◆ | +5.7 points◆ | -0.1 points | -27.5 points◆ |
Fiscal periods marked for changes
Earlier fiscal periods (9)
- 2015Net sales year on year +23.0%, Ordinary income (loss) as a share of revenue -51.8 points
- 2016Net sales year on year +88.1%, Ordinary income (loss) as a share of revenue -29.1 points
- 2017Ordinary income (loss) as a share of revenue +35.2 points
- 2018Net sales year on year -26.4%, Ordinary income (loss) as a share of revenue -26.4 points
- 2019Ordinary income (loss) as a share of revenue +43.3 points
- 2020Ordinary income (loss) as a share of revenue -16.7 points
- 2021Ordinary income (loss) as a share of revenue +13.0 points
- 2022Net sales year on year +73.7%, Ordinary income (loss) as a share of revenue +38.6 points
- 2023Net sales year on year +32.2%, Ordinary income (loss) as a share of revenue +18.7 points
- 2024Ordinary income (loss) as a share of revenue +5.7 points, Ordinary income (loss) loss to profit
- 2025Net sales year on year +22.7%
- 2026Net sales year on year -25.0%, Ordinary income (loss) as a share of revenue -27.5 points, Ordinary income (loss) profit to loss
ReproCELL
Earnings and net assets per share over time
Unit yenSource Annual securities reports
Consolidated indicators (14 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | ¥2.2 billion | ¥3.0 billion | ¥2.4 billion | ¥3.0 billion | ¥2.2 billion |
| Ordinary income (loss) | ¥-0.5 billion | ¥-0.1 billion | ¥40.19 million | ¥45.05 million | ¥-0.6 billion |
| Net income (loss) attributable to owners of parent | ¥-0.6 billion | ¥-0.3 billion | ¥-31.41 million | ¥0.1 billion | ¥-0.6 billion |
| Comprehensive income | ¥-0.6 billion | ¥-0.3 billion | ¥0.1 billion | ¥-56.68 million | ¥-0.2 billion |
| Net assets | ¥7.3 billion | ¥7.6 billion | ¥8.3 billion | ¥9.0 billion | ¥8.8 billion |
| Total assets | ¥8.1 billion | ¥8.4 billion | ¥9.1 billion | ¥9.7 billion | ¥9.7 billion |
| Net assets per share | 88.11 yen | 89.01 yen | 93.41 yen | 94.89 yen | 93.09 yen |
| Basic earnings (loss) per share | -7.57 yen | -3.62 yen | -0.37 yen | 1.11 yen | -6.25 yen |
| Equity-to-asset ratio | 89.5% | 90.7% | 91.8% | 92.9% | 91.7% |
| Return on equity | Could not be retrieved | Could not be retrieved | Could not be retrieved | 1.2% | Could not be retrieved |
| Net cash provided by (used in) operating activities | ¥-0.2 billion | ¥-0.1 billion | ¥-11.45 million | ¥6.29 million | ¥-0.4 billion |
| Net cash provided by (used in) investing activities | ¥-2.1 billion | ¥-1.1 billion | ¥0.4 billion | ¥-0.8 billion | ¥57.94 million |
| Net cash provided by (used in) financing activities | ¥2.4 billion | ¥0.5 billion | ¥0.5 billion | ¥0.7 billion | Could not be retrieved |
| Cash and cash equivalents | ¥2.6 billion | ¥1.9 billion | ¥2.9 billion | ¥2.8 billion | ¥2.6 billion |
Parent only indicators (10 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | ¥1.3 billion | ¥1.6 billion | ¥0.9 billion | ¥1.0 billion | ¥0.6 billion |
| Ordinary income (loss) | ¥-0.4 billion | ¥-0.1 billion | ¥-61.96 million | ¥-0.3 billion | ¥-0.3 billion |
| Net income (loss) | ¥-0.5 billion | ¥-0.3 billion | ¥-0.2 billion | ¥-0.3 billion | ¥-0.3 billion |
| Capital stock | ¥1.7 billion | ¥2.0 billion | ¥2.3 billion | ¥2.7 billion | ¥2.7 billion |
| Total number of issued shares (common stock) | 82,270,891 shares | 85,141,191 shares | 89,013,591 shares | 94,802,891 shares | 95,147,891 shares |
| Net assets | ¥7.5 billion | ¥7.9 billion | ¥8.4 billion | ¥8.6 billion | ¥8.7 billion |
| Total assets | ¥8.2 billion | ¥8.4 billion | ¥8.8 billion | ¥9.0 billion | ¥9.2 billion |
| Net assets per share | 91.73 yen | 92.42 yen | 94.05 yen | 91.29 yen | 91.6 yen |
| Basic earnings (loss) per share | -7.13 yen | -3.52 yen | -2.4 yen | -3.29 yen | -3.6 yen |
| Equity-to-asset ratio | 92.1% | 93.8% | 95.3% | 95.9% | 95.0% |
Shareholder composition
Share ownership by holder category
ReproCELL
Unit %Source Annual securities reports
- Financial institutions0.08%
- Securities firms1.50%
- Other corporations5.26%
- Foreign holders (institutions)1.78%
- Foreign holders (individuals)1.19%
- Individuals and others90.16%
Major shareholders
| Rank | Shareholder | Shareholding ratio | Shares held |
|---|---|---|---|
| 1 | 横山 周史 | 1.21% | 1,158,950 |
| 2 | 中野 暁 | 1.05% | 1,000,000 |
| 3 | 上田八木短資株式会社 | 0.87% | 832,400 |
| 4 | 五十畑 輝夫 | 0.87% | 828,600 |
| 5 | STATE STREET BANK AND TRUST COMPANY 505223(常任代理人 株式会社みずほ銀行) | 0.76% | 728,900 |
| 6 | 株式会社日本生物材料センター | 0.59% | 567,600 |
| 7 | 中辻 憲夫 | 0.52% | 500,000 |
| 8 | 椎橋 正則 | 0.49% | 470,800 |
| 9 | 旭化成酸素株式会社 | 0.47% | 455,000 |
| 10 | 荒井 憲一 | 0.47% | 453,900 |
Research and development expenses and capital expenditure
| Fiscal year | Research and development | Capital expenditure |
|---|---|---|
| FY ending 3/2026 | ¥0.6 billion | ¥98.39 million |
| FY ending 3/2025 | ¥0.5 billion | Could not be retrieved |
| FY ending 3/2021 | ¥0.7 billion | ¥64.27 million |
| FY ending 3/2020 | ¥0.5 billion | Could not be retrieved |
| FY ending 3/2017 | ¥0.3 billion | Could not be retrieved |
| FY ending 3/2016 | ¥0.3 billion | Could not be retrieved |
Research and development expenses and capital expenditure by segment (FY ending 3/2026)
| Segment | Research and development | Capital expenditure |
|---|---|---|
| 研究支援事業 | ¥0.4 billion | ¥36.53 million |
| Medical business | ¥0.2 billion | ¥55.35 million |
Revenue scale in the same industry
ReproCELL
Source Annual securities reports of each company
Chemicals: 212 companies · revenue · largest first・each company’s latest fiscal year・consolidated (parent-only where no consolidated figures)・Disclosed
- 1 Mitsubishi Chemical GloupFY Mar 2026 ¥3.7T
- 2 Asahi KaseiFY Mar 2026 ¥3.1T
- 3 Shin-Etsu ChemicalFY Mar 2026 ¥2.6T
- … 202 companies
- 206 atectFY Mar 2026 ¥3.4B
- 207 IVY COSMETICSFY Mar 2026 ¥2.6B
- 208 ReproCELLThis companyFY Mar 2026 ¥2.2B
- 209 HOSOYA PYRO-ENGINEERINGFY Mar 2026 ¥2.1B
- 210 WaqooFY Sep 2025 ¥2.0B
- … 2 companies
Workforce information
Administrative filings and published information
Subsidy award information
| Date approved | Subsidy | Ministry | Amount |
|---|---|---|---|
| 2021-04-01 | 令和3年度中小企業経営支援等対策費補助金(戦略的基盤技術高度化支援事業)(汎用性の高い遺伝子編集用iPS細胞株の開発と販売および同iPS細胞株を利用した高機能型膵臓β細胞の開発と事業化) | 経済産業省 | ¥20.00 million |
| 2020-04-30 | 令和2年度中小企業経営支援等対策費補助金(戦略的基盤技術高度化支援事業)(汎用性の高い遺伝子編集用iPS細胞株の開発と販売および同iPS細胞株を利用した高機能型膵臓β細胞の開発と事業化) | 経済産業省 | ¥30.00 million |
| 2019-08-26 | 令和元年度中小企業経営支援等対策費補助金(戦略的基盤技術高度化支援事業)(汎用性の高い遺伝子編集用iPS細胞株の開発と販売および同iPS細胞株を利用した高機能型膵臓β細胞の開発と事業化) | 経済産業省 | ¥20.00 million |
| 2019-08-26 | 令和元年度中小企業経営支援等対策費補助金(戦略的基盤技術高度化支援事業)(汎用性の高い遺伝子編集用iPS細胞株の開発と販売および同iPS細胞株を利用した高機能型膵臓β細胞の開発と事業化) | 経済産業省 | ¥30.00 million |
Audit and disclosure information
| Item | Value |
|---|---|
| Audit firm | 監査法人Bloom |
| Audit fees (this year, total) | ¥37.00 million |
| Non-audit fees (this year, total) | Not applicable |
| Going concern note | Stated as not applicable |
| Accounting standard | Japanese GAAP |
Related books, articles and videos
Sources and methodology
Retrieved disclosed figures
Major management indicators (5 years) (22 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Comprehensive income | ¥-0.2 billion | Consolidated |
| Net cash provided by (used in) operating activities | ¥-0.4 billion | Consolidated |
| Net sales | ¥2.2 billion | Consolidated |
| Net cash provided by (used in) investing activities | ¥57.94 million | Consolidated |
| Cash and cash equivalents | ¥2.6 billion | Consolidated |
| Net assets | ¥8.8 billion | Consolidated |
| Ordinary income (loss) | ¥-0.6 billion | Consolidated |
| Total assets | ¥9.7 billion | Consolidated |
| Equity-to-asset ratio | 91.7% | Consolidated |
| Net income (loss) attributable to owners of parent | ¥-0.6 billion | Consolidated |
| Basic earnings (loss) per share | -6.25 yen | Consolidated |
| Net assets per share | 93.09 yen | Consolidated |
| Net sales | ¥0.6 billion | Parent only |
| Net income (loss) | ¥-0.3 billion | Parent only |
| Total number of issued shares (common stock) | 95,147,891 shares | Parent only |
| Net assets | ¥8.7 billion | Parent only |
| Ordinary income (loss) | ¥-0.3 billion | Parent only |
| Total assets | ¥9.2 billion | Parent only |
| Equity-to-asset ratio | 95.0% | Parent only |
| Capital stock | ¥2.7 billion | Parent only |
| Basic earnings (loss) per share | -3.6 yen | Parent only |
| Net assets per share | 91.6 yen | Parent only |
Employees (9 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Number of employees | 101 people | Consolidated |
| Number of employees | 101 people | Consolidated |
| Average length of service (years) | 5 years | Parent only |
| Average length of service months | 6 months | Parent only |
| Average annual salary | ¥6.15 million | Parent only |
| Average age (years) | 34.2 years old | Parent only |
| Number of employees | 30 people | Parent only |
| Number of employees | 30 people | Parent only |
| Number of employees | 30 people | Parent only |
Other disclosed items (12 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Net sales to external customers | ¥2.2 billion | Consolidated |
| Average number of temporary employees | 9 people | Consolidated |
| Average number of temporary employees | 9 people | Consolidated |
| Number of associates accounted for using equity method | 0 companies | Consolidated |
| Increase in property plant and equipment and intangible assets | ¥98.39 million | Consolidated |
| Write-downs of inventories | ¥2.99 million | Consolidated |
| Depreciation | ¥72.25 million | Consolidated |
| Number of consolidated subsidiaries | 5 companies | Consolidated |
| Average number of temporary employees | 7 people | Parent only |
| Average number of temporary employees | 7 people | Parent only |
| Average number of temporary employees | 7 people | Parent only |
| Total return on the share price index | 179.0% | Parent only |
Shares (12 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Number of shares held | 6,996,150 shares | Consolidated |
| Total number of shares held treasury shares etc | 117,200 shares | Consolidated |
| Number of shares | 95,147,891 shares | Consolidated |
| Shareholding ratio treasury shares etc | 0.1% | Consolidated |
| Shareholding ratio | 7.4% | Consolidated |
| Number of shares held in own name treasury shares etc | 117,200 shares | Consolidated |
| Number of voting rights | 949,796 units | Consolidated |
| Carrying amount on the balance sheet | ¥0.8 billion | Consolidated |
| Carrying amount on the balance sheet | ¥40.70 million | Consolidated |
| Number of issues | 3 issues | Consolidated |
| Number of issues | 1 issues | Consolidated |
| Total shareholder return | 42.6% | Parent only |
Research and development (3 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period | ¥0.6 billion | Consolidated |
| Research and development expenses | ¥0.6 billion | Consolidated |
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period | ¥0.3 billion | Parent only |
Property and facilities (1 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Capital expenditures | ¥98.39 million | Consolidated |
Audit (2 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Fees for audit and attestation services - reporting company | ¥37.00 million | Consolidated |
| Fees for audit and attestation services - total | ¥37.00 million | Consolidated |
Accounts unique to this company (5 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Revenue | ¥0.4 billion | Consolidated |
| Revenue | ¥1.2 billion | Consolidated |
| Change in average annual salary from the previous year | 5.7% | Parent only |
| Revenue | ¥0.2 billion | Parent only |
| Revenue | ¥0.5 billion | Parent only |
Balance sheet (109 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Other | ¥2.49 million | Consolidated |
| Other | ¥58.40 million | Consolidated |
| Other | ¥0.2 billion | Consolidated |
| Other | ¥0.2 billion | Consolidated |
| Other | ¥8.42 million | Consolidated |
| Valuation difference on available-for-sale securities | ¥0.3 billion | Consolidated |
| Goodwill | ¥5.43 million | Consolidated |
| Goodwill | ¥5.43 million | Consolidated |
| Work in process | ¥69.66 million | Consolidated |
| Retained earnings | ¥-0.5 billion | Consolidated |
| Advances received | ¥0.1 billion | Consolidated |
| Raw materials and supplies | ¥79.85 million | Consolidated |
| Merchandise and finished goods | ¥0.1 billion | Consolidated |
| Non-current liabilities | ¥0.2 billion | Consolidated |
| Non-current assets | ¥2.3 billion | Consolidated |
| Accounts receivable - trade | ¥0.3 billion | Consolidated |
| Contract liabilities | ¥40.67 million | Consolidated |
| Tools, furniture and fixtures | ¥0.2 billion | Consolidated |
| Tools, furniture and fixtures | ¥0.1 billion | Consolidated |
| Buildings and structures | ¥61.16 million | Consolidated |
| Buildings and structures, net | ¥24.58 million | Consolidated |
| Investments and other assets | ¥2.0 billion | Consolidated |
| Investment securities | ¥1.9 billion | Consolidated |
| Securities | ¥3.9 billion | Consolidated |
| Property, plant and equipment | ¥0.3 billion | Consolidated |
| Income taxes payable | ¥25.54 million | Consolidated |
| Accounts payable - other | ¥87.37 million | Consolidated |
| Shareholders' equity | ¥8.5 billion | Consolidated |
| Machinery, equipment and vehicles | ¥0.2 billion | Consolidated |
| Machinery, equipment and vehicles, net | ¥0.1 billion | Consolidated |
| Current liabilities | ¥0.6 billion | Consolidated |
| Current assets | ¥7.3 billion | Consolidated |
| Accumulated depreciation | ¥-85.38 million | Consolidated |
| Accumulated depreciation | ¥-36.58 million | Consolidated |
| Accumulated depreciation | ¥-92.42 million | Consolidated |
| Foreign currency translation adjustment | ¥59.35 million | Consolidated |
| Intangible assets | ¥13.85 million | Consolidated |
| Cash and cash equivalents | ¥2.6 billion | Consolidated |
| Cash and deposits | ¥2.6 billion | Consolidated |
| Net assets | ¥8.8 billion | Consolidated |
| Net assets | ¥8.8 billion | Consolidated |
| Total assets | ¥9.7 billion | Consolidated |
| Total assets | ¥9.7 billion | Consolidated |
| Deferred tax liabilities | ¥0.2 billion | Consolidated |
| Deferred tax assets | ¥59.16 million | Consolidated |
| Treasury stock | ¥-0.92 million | Consolidated |
| Valuation and translation adjustments | ¥0.4 billion | Consolidated |
| Liabilities | ¥0.8 billion | Consolidated |
| Liabilities and net assets | ¥9.7 billion | Consolidated |
| Accounts payable - trade | ¥0.1 billion | Consolidated |
| Allowance for doubtful accounts | ¥-5.05 million | Consolidated |
| Allowance for doubtful accounts | ¥-4.54 million | Consolidated |
| Capital surplus | ¥6.3 billion | Consolidated |
| Capital stock | ¥2.7 billion | Consolidated |
| Asset retirement obligations | ¥9.12 million | Consolidated |
| Provision for bonuses | ¥8.71 million | Consolidated |
| Other | ¥2.46 million | Parent only |
| Other | ¥51.01 million | Parent only |
| Other | ¥0.69 million | Parent only |
| Other | ¥28.89 million | Parent only |
| Other | ¥0.05 million | Parent only |
| Valuation difference on available-for-sale securities | ¥0.3 billion | Parent only |
| Software | ¥6.70 million | Parent only |
| Work in process | ¥8.74 million | Parent only |
| Retained earnings | ¥-0.6 billion | Parent only |
| Advances received | ¥99.44 million | Parent only |
| Prepaid expenses | ¥71.77 million | Parent only |
| Advance payments trade | ¥24.69 million | Parent only |
| Raw materials and supplies | ¥42.70 million | Parent only |
| Merchandise and finished goods | ¥37.64 million | Parent only |
| Non-current liabilities | ¥0.2 billion | Parent only |
| Non-current assets | ¥2.8 billion | Parent only |
| Accounts receivable - trade | ¥79.13 million | Parent only |
| Contract liabilities | ¥3.83 million | Parent only |
| Tools, furniture and fixtures | ¥87.19 million | Parent only |
| Buildings | ¥23.81 million | Parent only |
| Investments and other assets | ¥2.7 billion | Parent only |
| Investment securities | ¥1.9 billion | Parent only |
| Securities | ¥3.9 billion | Parent only |
| Property, plant and equipment | ¥0.1 billion | Parent only |
| Accounts receivable - other | ¥25.84 million | Parent only |
| Income taxes payable | ¥25.27 million | Parent only |
| Accrued expenses | ¥5.02 million | Parent only |
| Accounts payable - other | ¥80.09 million | Parent only |
| Shareholders' equity | ¥8.4 billion | Parent only |
| Current liabilities | ¥0.3 billion | Parent only |
| Current assets | ¥6.4 billion | Parent only |
| Intangible assets | ¥6.75 million | Parent only |
| Cash and deposits | ¥2.1 billion | Parent only |
| Net assets | ¥8.7 billion | Parent only |
| Net assets | ¥8.7 billion | Parent only |
| Total assets | ¥9.2 billion | Parent only |
| Deferred tax liabilities | ¥0.2 billion | Parent only |
| Retained earnings brought forward | ¥-0.6 billion | Parent only |
| Treasury stock | ¥-0.92 million | Parent only |
| Valuation and translation adjustments | ¥0.3 billion | Parent only |
| Liabilities | ¥0.5 billion | Parent only |
| Liabilities and net assets | ¥9.2 billion | Parent only |
| Accounts payable - trade | ¥45.68 million | Parent only |
| Allowance for doubtful accounts | ¥-54.17 million | Parent only |
| Capital surplus | ¥6.3 billion | Parent only |
| Legal capital surplus | ¥6.3 billion | Parent only |
| Capital stock | ¥2.7 billion | Parent only |
| Asset retirement obligations | ¥9.12 million | Parent only |
| Provision for bonuses | ¥8.71 million | Parent only |
| Shares of subsidiaries and associates | ¥0.5 billion | Parent only |
| Long-term receivables affiliates | ¥92.42 million | Parent only |
| Long-term loans receivable from subsidiaries and affiliates | ¥0.2 billion | Parent only |
| Deposits received | ¥4.76 million | Parent only |
Statement of income (90 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Other | ¥11.42 million | Consolidated |
| Other | ¥1.93 million | Consolidated |
| Other comprehensive income | ¥0.4 billion | Consolidated |
| Valuation difference on available for sale securities net of tax | ¥0.3 billion | Consolidated |
| Amortization of goodwill | ¥2.71 million | Consolidated |
| Amortization of goodwill | ¥2.71 million | Consolidated |
| Amortization of goodwill | ¥2.71 million | Consolidated |
| Comprehensive income | ¥-0.2 billion | Consolidated |
| Interest income | ¥87.80 million | Consolidated |
| Operating income | ¥-0.9 billion | Consolidated |
| Non-operating income | ¥0.3 billion | Consolidated |
| Non-operating expenses | ¥29.90 million | Consolidated |
| Net cash provided by (used in) operating activities | ¥-0.4 billion | Consolidated |
| Cost of sales | ¥1.2 billion | Consolidated |
| Gross profit (loss) | ¥1.0 billion | Consolidated |
| Net sales | ¥2.2 billion | Consolidated |
| Net sales | ¥2.2 billion | Consolidated |
| Net income | ¥-0.6 billion | Consolidated |
| Net income | ¥-0.6 billion | Consolidated |
| Net income (loss) | ¥-0.6 billion | Consolidated |
| Net income (loss) | ¥-0.6 billion | Consolidated |
| Service revenue | ¥0.9 billion | Consolidated |
| Directors' compensations | ¥62.40 million | Consolidated |
| Net cash provided by (used in) investing activities | ¥57.94 million | Consolidated |
| Share of loss of investments accounted for using equity method | ¥27.97 million | Consolidated |
| Share of other comprehensive income of investments accounted for using equity method | ¥13.58 million | Consolidated |
| Fee expenses | ¥0.1 billion | Consolidated |
| Issuance of new shares | ¥62.45 million | Consolidated |
| Income taxes - current | ¥4.30 million | Consolidated |
| Income taxes | ¥4.30 million | Consolidated |
| Depreciation | ¥19.27 million | Consolidated |
| Impairment loss | ¥6.05 million | Consolidated |
| Impairment loss | ¥6.05 million | Consolidated |
| Foreign exchange gains | ¥0.1 billion | Consolidated |
| Foreign currency translation adjustment net of tax | ¥51.92 million | Consolidated |
| Extraordinary loss | ¥6.05 million | Consolidated |
| Effect of exchange rate change on cash and cash equivalents | ¥0.1 billion | Consolidated |
| Net increase (decrease) in cash and cash equivalents | ¥-0.2 billion | Consolidated |
| Research and development expenses | ¥0.6 billion | Consolidated |
| Income (loss) before income taxes | ¥-0.6 billion | Consolidated |
| Income (loss) before income taxes | ¥-0.6 billion | Consolidated |
| Ordinary income | ¥-0.6 billion | Consolidated |
| Ordinary income | ¥-0.6 billion | Consolidated |
| Salaries and allowances | ¥0.5 billion | Consolidated |
| Subsidy income | ¥99.90 million | Consolidated |
| Subsidy income | ¥99.90 million | Consolidated |
| Cost of finished goods sold | ¥0.8 billion | Consolidated |
| Product sales revenue | ¥1.3 billion | Consolidated |
| Comprehensive income attributable to owners of parent | ¥-0.2 billion | Consolidated |
| Selling, general and administrative expenses | ¥1.9 billion | Consolidated |
| Provision of allowance for doubtful accounts | ¥5.50 million | Consolidated |
| Bonuses and allowance | ¥5.54 million | Consolidated |
| Provision for bonuses | ¥3.55 million | Consolidated |
| Other | ¥1.47 million | Parent only |
| Other | ¥1.60 million | Parent only |
| Interest income | ¥17.68 million | Parent only |
| Operating income | ¥-0.6 billion | Parent only |
| Non-operating income | ¥0.3 billion | Parent only |
| Non-operating expenses | ¥24.46 million | Parent only |
| Cost of sales | ¥0.4 billion | Parent only |
| Gross profit (loss) | ¥0.2 billion | Parent only |
| Net sales | ¥0.6 billion | Parent only |
| Net income (loss) | ¥-0.3 billion | Parent only |
| Net income (loss) | ¥-0.3 billion | Parent only |
| Service revenue | ¥0.2 billion | Parent only |
| Directors' compensations | ¥62.40 million | Parent only |
| Loss on investments in partnership | ¥22.86 million | Parent only |
| Fee expenses | ¥55.92 million | Parent only |
| Issuance of new shares | ¥62.45 million | Parent only |
| Transportation and communication expenses | ¥3.78 million | Parent only |
| Interest on securities | ¥68.42 million | Parent only |
| Share-based payment expenses | ¥46.33 million | Parent only |
| Income taxes - current | ¥1.66 million | Parent only |
| Income taxes | ¥1.66 million | Parent only |
| Depreciation | ¥3.66 million | Parent only |
| Impairment loss | ¥6.05 million | Parent only |
| Foreign exchange gains | ¥0.1 billion | Parent only |
| Extraordinary loss | ¥8.01 million | Parent only |
| Research and development expenses | ¥0.3 billion | Parent only |
| Taxes and dues | ¥49.75 million | Parent only |
| Income (loss) before income taxes | ¥-0.3 billion | Parent only |
| Ordinary income | ¥-0.3 billion | Parent only |
| Salaries and allowances | ¥0.2 billion | Parent only |
| Subsidy income | ¥99.90 million | Parent only |
| Cost of finished goods sold | ¥0.2 billion | Parent only |
| Product sales revenue | ¥0.4 billion | Parent only |
| Selling, general and administrative expenses | ¥0.9 billion | Parent only |
| Provision of allowance for doubtful accounts | ¥1.96 million | Parent only |
| Bonuses and allowance | ¥5.54 million | Parent only |
| Provision for bonuses | ¥3.55 million | Parent only |
Statement of changes in equity (4 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Total changes during the period | ¥-0.1 billion | Consolidated |
| Net changes in items other than shareholders' equity | ¥0.4 billion | Consolidated |
| Total changes during the period | ¥60.79 million | Parent only |
| Net changes in items other than shareholders' equity | ¥0.3 billion | Parent only |
Statement of cash flows (23 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Other | ¥-35.13 million | Consolidated |
| Amortization of goodwill | ¥2.71 million | Consolidated |
| Increase decrease in notes and accounts payable trade | ¥3.26 million | Consolidated |
| Interest and dividends income received | ¥82.85 million | Consolidated |
| Interest and dividend income | ¥-87.80 million | Consolidated |
| Decrease increase in notes and accounts receivable trade | ¥0.1 billion | Consolidated |
| Increase (decrease) in contract liabilities | ¥-14.12 million | Consolidated |
| Subtotal | ¥-0.6 billion | Consolidated |
| Equity in earnings losses of affiliates | ¥27.97 million | Consolidated |
| Purchase of short term and long term investment securities | ¥-1.0 billion | Consolidated |
| Proceeds from sales and redemption of investment securities | ¥1.2 billion | Consolidated |
| Purchase of property plant and equipment | ¥-98.22 million | Consolidated |
| Increase (decrease) in accounts payable-other | ¥39.05 million | Consolidated |
| Share-based payment expenses | ¥46.33 million | Consolidated |
| Decrease (increase) in inventories | ¥5.33 million | Consolidated |
| Income taxes paid | ¥-4.32 million | Consolidated |
| Depreciation | ¥72.25 million | Consolidated |
| Impairment loss | ¥6.05 million | Consolidated |
| Foreign exchange loss (gain) | ¥-74.10 million | Consolidated |
| Proceeds from subsidy income | ¥89.69 million | Consolidated |
| Subsidy income | ¥-99.90 million | Consolidated |
| Increase (decrease) in allowance for doubtful accounts | ¥0.66 million | Consolidated |
| Increase (decrease) in provision for bonuses | ¥-3.26 million | Consolidated |
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Net cash provided by (used in) operating activities | ¥-0.4 billion | Consolidated | Disclosed |
| Number of employees | 101 | Consolidated | Disclosed |
| Net assets | ¥8.8 billion | Consolidated | Disclosed |
| Net sales | ¥2.2 billion | Consolidated | Disclosed |
| Operating income | ¥-0.9 billion | Consolidated | Disclosed |
| Ordinary income | ¥-0.6 billion | Consolidated | Disclosed |
| Net income | ¥-0.6 billion | Consolidated | Disclosed |
| Total assets | ¥9.7 billion | Consolidated | Disclosed |
| Operating margin | -38.5% | Consolidated | Calculated |
| Net margin | -26.5% | Consolidated | Calculated |
| Sales per employee | 22114050 yen | Consolidated | Calculated |
| Total asset turnover | 0.23 times | Consolidated | Calculated |
| Net assets to total assets | 91.7% | Consolidated | Calculated |